Charles Schwab Investment Management Inc. Boosts Stake in ImmunityBio, Inc. (NASDAQ:IBRX)

Charles Schwab Investment Management Inc. raised its holdings in shares of ImmunityBio, Inc. (NASDAQ:IBRX) by 0.8% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,276,673 shares of the company’s stock after buying an additional 10,692 shares during the period. Charles Schwab Investment Management Inc. owned about 0.18% of ImmunityBio worth $3,268,000 at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. Stephens Inc. AR purchased a new position in ImmunityBio during the 4th quarter valued at $26,000. Captrust Financial Advisors purchased a new stake in shares of ImmunityBio during the third quarter valued at $41,000. Virtu Financial LLC bought a new position in shares of ImmunityBio in the third quarter worth about $51,000. Maia Wealth LLC purchased a new position in ImmunityBio in the 4th quarter worth about $37,000. Finally, Schechter Investment Advisors LLC bought a new stake in ImmunityBio during the 4th quarter valued at about $38,000. Hedge funds and other institutional investors own 8.58% of the company’s stock.

ImmunityBio Price Performance

ImmunityBio stock opened at $3.36 on Friday. ImmunityBio, Inc. has a 1-year low of $2.28 and a 1-year high of $10.53. The business has a fifty day moving average price of $3.12 and a 200-day moving average price of $3.60. The stock has a market capitalization of $2.87 billion, a price-to-earnings ratio of -3.65 and a beta of 0.82.

ImmunityBio (NASDAQ:IBRX) last issued its quarterly earnings results on Monday, March 3rd. The company reported ($0.15) earnings per share for the quarter, topping the consensus estimate of ($0.26) by $0.11. The business had revenue of $7.55 million during the quarter, compared to analyst estimates of $8.74 million. On average, equities research analysts anticipate that ImmunityBio, Inc. will post -0.92 earnings per share for the current fiscal year.

Analysts Set New Price Targets

IBRX has been the topic of a number of research reports. BTIG Research began coverage on shares of ImmunityBio in a research report on Friday, January 10th. They set a “buy” rating and a $6.00 target price on the stock. D. Boral Capital reissued a “buy” rating and issued a $30.00 price objective on shares of ImmunityBio in a research note on Thursday, March 13th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $8.00 target price on shares of ImmunityBio in a research report on Thursday, March 13th. One research analyst has rated the stock with a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $12.19.

About ImmunityBio

ImmunityBio, Inc, a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies.